An innovation to markedly improve liquid biopsy tests with 10-fold more cell-free DNA science.org/doi/10.1126/sc… science.org/doi/10.1126/sc… Science Magazine

Broad and Massachusetts Institute of Technology (MIT) scientists including sangeeta bhatia have developed two agents that could one day be given to patients shortly before a blood draw to allow physicians to better detect tumor DNA using liquid biopsy. broad.io/priming-agents…

Thank you Mass General Research Institute Mass General Cancer Center for highlighting our work on priming agents for liquid biopsies! massgeneral.org/news/research-…

Very excited to discuss our work on mAb priming agents for liquid biopsies!

This paper is really special. This was my first research project years ago, and it's amazing to finally see it out now in Nature Microbiology! Congratulations and big thanks to the whole team, especially Dylan Kotliar and @sidsraju! nature.com/articles/s4156…

Making blood tests for cancer detection more sensitive by making circulating tumor DNA stick around longer! Two nice strategies detailed in this paper from Massachusetts Institute of Technology (MIT) Broad Institute in Science Magazine

In an interview with Targeted Oncology, Shervin Tabrizi, MD, radiation oncologist, discussed the development of a 2-part priming strategy aimed at enhancing the sensitivity of liquid biopsies for cancer detection and monitoring. spklr.io/6016Wqdr

Final call! Don't miss out on our webinar discussing DNA-binding antibodies for sensitive liquid biopsies happening tomorrow, March 7th at 11:00 AM EST! Register today! hubs.li/Q02nnc7Z0 #Webinar #AntibodyEngineering #CancerDx #CancerDiagnostics #IVD

Missed our latest webinar? We’ve got you covered. Check out the recording of our latest webinar on developing sensitive liquid biopsies using antibodies as DNA-priming agents. Watch the recording here: hubs.li/Q02p5qcX0 #AntibodyEngineering #IVDs #CancerDiagnostics

In a cohort at average risk for colorectal cancer, a cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions. Full ECLIPSE study results: nej.md/3v0J319

Our work on priming agents for #ctDNA liquid biopsies highlighted on National Cancer Institute Cancer Currents Blog! cancer.gov/news-events/ca…

For all #MedStudents applying for #RadOnc ☢️ this #Match2025 (or just curious about rad onc in general), we have an opportunity for you learn more about our program. Harvard Radiation Oncology Residency Program Sign up today! forms.gle/rd5pb5X8DYKcZt… #ERAS #MedTwitter #MedEd

Very excited to share some of our work on priming agents for #cfDNA #LiquidBiopsies at the Next Generation Dx Summit this week!!